Accuray's new CyberKnife S7 completes treatment sessions in as little as 15 minutes
por John R. Fischer, Senior Reporter | June 18, 2020
Rad Oncology
Accuray launches the CyberKnife S7 System.
Radiotherapy manufacturer Accuray has launched the Cyberknife S7 System, a robotic and noninvasive solution that delivers all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) in as little as 15 minutes.
The next-generation CyberKnife platform utilizes speed, advanced precision and real-time AI-driven motion tracking and synchronization treatment delivery to treat cancerous and benign tumors throughout the body, as well as neurological disorders. Its debut in the U.S. will be at Geisinger Cancer Institute in northeastern Pennsylvania.
"We are proud to be the first center in the world to treat patients with the CyberKnife S7 System, an advanced device that will expand the scope of tumors we can treat,” said Dr. Anand Mahadevan, chairman of radiation oncology at Geisinger Cancer Institute, in a statement. “Knowing that the system will automatically adapt treatment delivery for patient or tumor movement gives us the confidence to use SRS and SBRT for intra- and extra-cranial disease sites throughout the body, providing meaningful benefits to our patients during and after treatment."
The advantages of SRS and SBRT as treatments is that patients receive very high doses of precise, hypofractionated radiation therapy that accurately targets tumors and are administered over just a few days, with a lower risk of side effects that can significantly impact the lives of patients. Conventional fractionation, in contrast, requires up to 35 visits.
With its Synchrony motion synchronization technology, the CyberKnife can apply AI to adapt radiation delivery in real time to any movements by the patient and/or tumor throughout the course of treatment. This includes shifts in patient position, as well as movement caused by breathing, coughing, muscles tensing and relaxing, and fluids and gasses displacing internal organs.
The robotic design enables radiation to be delivered from potentially thousands of different angles. The more angles and points in space from which to approach the tumor, the better a physician can maximize radiation dose delivered to the tumor and minimize dose to surrounding healthy tissue.
The solution is also the only device that offers sub-millimetric stereotactic treatments anywhere in the body without the need for human intervention. It delivers accurate, sub-millimetric, motion synchronized, (ultra) hypofractionated treatments in as little as 15 minutes with Synchrony and the VOLO Optimizer, both of which facilitate the patient throughput required.
The next-generation CyberKnife platform utilizes speed, advanced precision and real-time AI-driven motion tracking and synchronization treatment delivery to treat cancerous and benign tumors throughout the body, as well as neurological disorders. Its debut in the U.S. will be at Geisinger Cancer Institute in northeastern Pennsylvania.
"We are proud to be the first center in the world to treat patients with the CyberKnife S7 System, an advanced device that will expand the scope of tumors we can treat,” said Dr. Anand Mahadevan, chairman of radiation oncology at Geisinger Cancer Institute, in a statement. “Knowing that the system will automatically adapt treatment delivery for patient or tumor movement gives us the confidence to use SRS and SBRT for intra- and extra-cranial disease sites throughout the body, providing meaningful benefits to our patients during and after treatment."
The advantages of SRS and SBRT as treatments is that patients receive very high doses of precise, hypofractionated radiation therapy that accurately targets tumors and are administered over just a few days, with a lower risk of side effects that can significantly impact the lives of patients. Conventional fractionation, in contrast, requires up to 35 visits.
With its Synchrony motion synchronization technology, the CyberKnife can apply AI to adapt radiation delivery in real time to any movements by the patient and/or tumor throughout the course of treatment. This includes shifts in patient position, as well as movement caused by breathing, coughing, muscles tensing and relaxing, and fluids and gasses displacing internal organs.
The robotic design enables radiation to be delivered from potentially thousands of different angles. The more angles and points in space from which to approach the tumor, the better a physician can maximize radiation dose delivered to the tumor and minimize dose to surrounding healthy tissue.
The solution is also the only device that offers sub-millimetric stereotactic treatments anywhere in the body without the need for human intervention. It delivers accurate, sub-millimetric, motion synchronized, (ultra) hypofractionated treatments in as little as 15 minutes with Synchrony and the VOLO Optimizer, both of which facilitate the patient throughput required.
1(current)
You Must Be Logged In To Post A CommentRegistroRegistrarse es Gratis y Fácil. Disfruta de los beneficios del Mercado de Equipos Médicos Nuevos y Usados líder en el mundo. ¡Regístrate ahora! |
|
